ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $78.66, but acceptable to hold if already in. Reasons: Concentration risk — Product: Cortrophin Gel; Concentration risk — Supplier: single source of API for each product.
ANI Pharmaceuticals is a diversified biopharma company with three businesses: Rare Disease (Cortrophin Gel, ILUVIEN), Generics (120+ products), and Brands. The company owns three manufacturing facilities in Baudette, MN and East Windsor, NJ, and acquired Alimera Sciences... Read more
Hold if already holding. Not a fresh buy at $78.66, but acceptable to hold if already in. Reasons: Concentration risk — Product: Cortrophin Gel; Concentration risk — Supplier: single source of API for each product. Chart setup: RSI 51 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 6.3/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCortrophin Gel10-K Item 1A: 'a significant portion of our net product revenues were derived from the sale of Cotrophin Gel, and we expect that sales of Cortrophin Gel will continue to account for a significant portion of our net product revenues in future years'
- HIGHSuppliersingle source of API for each product10-K Item 1A: 'Generally, only a single source of API is qualified for use in each product due to the costs and time required to validate a second source of supply'
Material Events(8-K, last 90d)
- 2026-04-07Item 4.01HIGHANI Pharmaceuticals dismissed EisnerAmper LLP as independent registered public accounting firm effective April 1, 2026. No successor named in visible filing text. No disagreements with EisnerAmper on accounting principles or practices were reported.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $78.66, but acceptable to hold if already in. Reasons: Concentration risk — Product: Cortrophin Gel; Concentration risk — Supplier: single source of API for each product. Chart setup: RSI 51 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $96.24 (+22.3%), stop $74.08 (−6.2%), A.R:R 3.3:1. Score 6.3/10, moderate confidence.
Take-profit target: $96.24 (+22.4% upside). Target $96.24 (+22.3%), stop $74.08 (−6.2%), A.R:R 3.3:1. Stop-loss: $74.08.
Concentration risk — Product: Cortrophin Gel; Concentration risk — Supplier: single source of API for each product; Leverage penalty (D/E 1.2): -0.5.
ANI Pharmaceuticals, Inc. trades at a P/E of 23.5 (forward 7.4). TrendMatrix value score: 8.1/10. Verdict: Hold.
14 analysts cover ANIP with a consensus score of 4.2/5. Average price target: $111.
What does ANI Pharmaceuticals, Inc. do?ANI Pharmaceuticals is a diversified biopharma company with three businesses: Rare Disease (Cortrophin Gel, ILUVIEN),...
ANI Pharmaceuticals is a diversified biopharma company with three businesses: Rare Disease (Cortrophin Gel, ILUVIEN), Generics (120+ products), and Brands. The company owns three manufacturing facilities in Baudette, MN and East Windsor, NJ, and acquired Alimera Sciences (ILUVIEN/YUTIQ) in September 2024. A significant portion of 2025 net product revenues was derived from Cortrophin Gel, and one domestic supplier accounted for approximately 17% of raw materials/API purchases.